MedTrace Logo

Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).

NCT00795509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 374

Last updated 2012-07-09

Study results available
· View outcomes & findings →

Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

Tolterodine tartrate

Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. " The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-03-31
Completion
2011-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00795509 on ClinicalTrials.gov